GLP-1s are highly effective at controlling blood sugar and slowing down gastric processes, but they are also highly effective (so to speak) at bringing on side effects like constipation, nausea, and abdominal pain that, if untreated, will impact adherence and, in turn, short and long term results
How is this possible
Technically N-L-gamma-glutamyl-cysteinyl glycine or L-glutathione, the molecule has a sulfhydryl (SH) group on the cysteinyl portion, which accounts for its strong electron-donating character
Whether liver-specific GSH synthesis was responsible for downregulated lipogenic gene expression and reduced serum triglycerides or whether these phenotypes were a byproduct of a liver-independent process in Gclc KO mice was unclear
Combination signalling and synergy investigations: Co-administration studies with GLP-1 receptor agonists or other metabolic peptides to probe additive or synergistic effects on body weight and glucose parameters at the preclinical level
Impact statement Abnormal metabolism is a common feature preceding several autoimmune and inflammatory diseases